Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 30;9(11):668.
doi: 10.3390/biom9110668.

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management

Isabelle Solassol  1   2 , Frédéric Pinguet  3 , Xavier Quantin  4
Affiliations
Review

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management

Isabelle Solassol et al. Biomolecules. .

Abstract

Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The discovery of several oncogenic driver mutations in patients with NSCLC has allowed the development of personalized treatments based on these specific molecular alterations, in particular in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene. Gefitinib, erlotinib, afatinib, and osimertinib are TK inhibitors (TKIs) that specifically target EGFR and are currently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first line treatment for sensitive EGFR-mutant patients. However, these four drugs are associated with severe adverse events (AEs) that can significantly impact patient health-related quality of life and patient monitoring. EGFR-TKIs are commonly used together with other types of medication that can substantially interact. Here, we review approaches used for the management of TKI-AEs in patients with advanced NSCLC to promote the benefits of treatments and minimize the risk of TKI treatment discontinuation. We also consider potential TKI-drug interactions and discuss the usefulness of plasma concentration monitoring TKIs based on chromatographic and mass spectrometry approaches to guide clinical decision-making. Adjusting the most appropriate therapeutic strategies and drug doses may improve the performance therapy and prognosis of patients with advanced EGFR-mutated NSCLC.

Keywords: NSCLC; TDM; TKIs; quantification; side effects.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hanna N., Johnson D., Temin S., Baker S., Jr., Brahmer J., Ellis P.M., Giaccone G., Hesketh P.J., Jaiyesimi I., Leighl N.B., et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 2017;35:3484–3515. doi: 10.1200/JCO.2017.74.6065. - DOI - PubMed
    1. Woodcock J. AstraZeneca Pharmaceuticals LP: Withdrawal of Approval of a New Drug Application for IRESSA. Fed. Regist. 2012;77:24723–24724.
    1. Astellas Pharma US I., Genen-Tech, Inc. Tarceva (erlotinib) Prescribing Information. [(accessed on 30 August 2015)]; Available online: www.accessdata. fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf.
    1. Boehringer Ingelheim. [(accessed on 30 August 2015)]; Available online: www.accessdata.fda.gov/drugsatfda_docs/label/2013/201292s000lbl.pdf.
    1. Rosell R., Moran T., Carcereny E., Quiroga V., Molina M.A., Costa C., Benlloch S., Taron M. Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Clin. Transl. Oncol. 2010;12:75–80. doi: 10.1007/S12094-010-0473-0. - DOI - PubMed

Publication types

MeSH terms